VKTX Viking Therapeutics, Inc.

QT26

Latest market price

27.28

+0.42+1.56%

Overview Short InterestFilings

VKTXQT26Viking Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

27.28+1.56%

News

Up 1.6% — Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet) (seekingalpha.com).

Medium confidence

Loading chart...

Signal & projected range

Earnings big miss — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

TARS+0.88%$74.85 ACAD-0.82%$20.59 CELC-0.25%$69.13 AMLX+0.63%$28.86 XENE-0.35%$37.41 ELVN-1.84%$44.25 TNGX+0.84%$22.72 IOVA-11.30%$8.48

Snapshot

Index	—	P/E	—	EPS (ttm)	-5.40	Insider Own	8.47%	Shs Outstand	127.17M	Perf Week	11.80%

Market Cap	3.47B	Forward P/E	—	EPS next Y	-5.13	Insider Trans	-1.75%	Shs Float	123.44M	Perf Month	-10.59%

Enterprise Value	2.76B	PEG	—	EPS next Q	—			Short Float	20.69%	Perf Quarter	-16.34%

Income	-627.00M	P/S	—	EPS this Y	—			Short Ratio	5.77	Perf Half Y	-9.07%

Sales	0.00	P/B	5.89	EPS next Y	—	ROA	-64.19%	Short Interest	25.54M	Perf YTD	-22.46%

Book/sh	4.63	P/C	3.61	EPS next 5Y	—	ROE	-117.35%	52W High	43.15 -36.78%	Perf Year	-22.54%

Cash/sh	7.55	P/FCF	—	EPS past 3/5Y	—	ROIC	-76.91%	52W Low	23.82 14.53%	Perf 3Y	155.67%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	6.25% 5.36%	Perf 5Y	373.61%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	1.77	Perf 10Y	2272.17%

Dividend Ex-Date	—	Quick Ratio	7.27	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	47.98	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	7.27	EPS Q/Q	-91.36%	SMA20	2.48%	Beta	0.73	Target Price	82.00

Payout	0.00%	Debt/Eq	0.43	Sales Q/Q	—	SMA50	-10.59%	Rel Volume	1.05	Prev Close	26.86

Employees	53	LT Debt/Eq	0.43	Earnings	Feb 10	SMA200	-15.81%	Avg Volume	4.84M	Price	27.28

IPO Date	Apr 28, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-45.81% —	Net Debt/EBITDA	—	Volume	5,085,871	Change	1.56%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-29-26	Reiterated	Goldman Sachs		$38 → $34
Oct-07-26	Reiterated	Truist Securities	Buy	$87 → $85
Sep-23-26	Reiterated	Truist Securities	Buy	$83 → $87
Sep-22-26	Reiterated	Oppenheimer	Outperform	$100
Sep-21-26	Reiterated	Oppenheimer	Outperform	$100
May-28-26	Initiated	Lake Street	Buy	$89
May-27-26	Reiterated	Truist Financial	Buy	$75 → $83
Apr-30-26	Reiterated	Morgan Stanley	Overweight	$99 → $95
Apr-30-26	Reiterated	Cantor Fitzgerald	Overweight	$105 → $100
Mar-12-26	Reiterated	Jefferies		$101

Latest News· Times ET

Oct-30-26

Oct-30-2601:11PM

VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?zacks.com

10:31AM

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Betzacks.com

Oct-29-26

Oct-29-2604:13PM

Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)seekingalpha.com

01:56PM

VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenseszacks.com

11:02AM

VKTX Q3 Earnings Call Highlights Obesity Pipeline Progresszacks.com

10:03AM

Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases247wallst.com

07:30AM

Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The Stockseekingalpha.com

02:05AM

Viking Therapeutics Q3 Earnings Call Highlightsmarketbeat.com

12:13AM

Viking (VKTX) Q3 2026 Earnings Call TranscriptYahoo

Oct-28-26

Oct-28-2608:50PM

Viking Therapeutics, Inc. (VKTX) Q3 2026 Earnings Call Transcriptseekingalpha.com

04:05PM

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Updateprnewswire.com

Oct-26-26

Oct-26-2611:06AM

Should You Buy Viking Therapeutics Stock Ahead of Q3 Results?zacks.com

Oct-25-26

Oct-25-2611:40AM

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28247wallst.com

Oct-23-26

Oct-23-2606:45PM

Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Marketzacks.com

Oct-22-26

Oct-22-2606:51PM

Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Knowzacks.com

Company

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	0	—	—	—	—	—
Gross Profit	0	0	0	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	62	48	49	37	—	—	—	—	—
Research and Development	586	345	102	64	—	—	—	—	—
Other Operating Expense	1	0	0	0	—	—	—	—	—
Operating Income	-649	-393	-151	-101	—	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	22	34	41	15	—	—	—	—	—
Net Income Before Taxes	-627	-360	-110	-86	—	—	—	—	—
Income Taxes	0	0	0	0	—	—	—	—	—
Consolidated Net Income	-627	-360	-110	-86	—	—	—	—	—
Net Income From Continuing Operations	-627	-360	-110	-86	—	—	—	—	—
Net Income	-627	-360	-110	-86	—	—	—	—	—
EPS (Recurring)	-5.40	-3.19	-1.01	-0.91	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-5.40	-3.19	-1.01	-0.91	—	—	—	—	—
EPS (Diluted)	-5.40	-3.19	-1.01	-0.91	—	—	—	—	—
EBITDA	-627	-359	-110	-86	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	118	113	109	94	—	—	—	—	—
Market Capitalization	3,219	3,975	4,386	1,749	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lian Brian	President & CEO	Jul 29 '26	Sale	33.32	148,517	4,947,888	2,572,441	Jul 29
ZANTE GREG	Chief Financial Officer	Jul 29 '26	Sale	33.47	21,217	710,141	212,204	Jul 29
Mancini Marianna	Chief Operating Officer	Jul 29 '26	Sale	33.47	18,217	609,636	422,760	Jul 29
Aubuchon Neil William	Chief Commercial Officer	Mar 10 '26	Buy	33.50	4,475	149,913	4,475	Mar 10
Mancini Marianna	Chief Operating Officer	Jan 05 '26	Sale	32.98	57,661	1,901,406	409,190	Jan 05
Lian Brian	President & CEO	Jan 05 '26	Sale	32.96	233,409	7,692,121	2,499,291	Jan 05
ZANTE GREG	Chief Financial Officer	Jan 05 '26	Sale	32.90	57,661	1,896,969	189,891	Jan 05
FOEHR MATTHEW W	Director	Jan 02 '26	Option Exercise	3.33	16,000	53,280	148,036	Jan 05
FOEHR MATTHEW W	Director	Jan 02 '26	Sale	35.11	16,000	561,694	132,036	Jan 05
ZANTE GREG	Chief Financial Officer	Oct 28 '25	Sale	35.00	6,185	216,481	173,592	Oct 28
Mancini Marianna	Chief Operating Officer	Oct 28 '25	Sale	35.00	6,185	216,492	382,467	Oct 28
Lian Brian	President & CEO	Oct 28 '25	Sale	35.01	38,989	1,364,923	2,419,109	Oct 28
Rowland Charles A Jr	Director	Oct 27 '25	Option Exercise	5.11	60,000	306,640	0	Oct 28
Rowland Charles A Jr	Director	Oct 27 '25	Sale	35.57	60,000	2,134,278	30,000	Oct 28
ZANTE GREG	Chief Financial Officer	Jul 03 '25	Sale	27.76	4,266	118,428	168,660	Jul 03

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.